Organisation paid for research Program year 2025 Source: CMS Open Payments

Appalachian Clinical Research

Neither a doctor nor a teaching hospital

Research payments

$1,425,347

1,014 payments

Through program year 2025, Appalachian Clinical Research is reported as receiving $1,425,347 in research payments, across 1,014 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $190,109 94
2024 Research $348,554 256
2023 Research $290,203 176
2022 Research $173,239 107
2021 Research $149,620 208
2020 Research $94,362 94
2019 Research $179,262 79

Breakdown

Who paid Research payments · program years 2019–2025
  1. Sanofi US Services Inc. $416,574 195 payments
  2. Chiesi USA, Inc. $335,447 298 payments
  3. GlaxoSmithKline, LLC. $320,917 187 payments
  4. AstraZeneca Pharmaceuticals LP $231,803 18 payments
  5. Novo Nordisk AS $60,392 241 payments
  6. Genzyme Corporation $43,243 70 payments
  7. Pfizer Inc. $16,971 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) $224,493 92 payments
  2. A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma $122,338 4 payments
  3. A Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Cont $109,352 71 payments
  4. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (Triton) $108,297 88 payments
  5. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation $92,504 67 payments
  6. Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD $80,800 1 payment
  7. A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD (TRITON) $61,105 86 payments
  8. A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp 500g) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR) (PILLAR) $51,980 53 payments
  9. Nn9535-4506 $50,619 95 payments
  10. Study name not reported $45,982 9 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record